Market Research Logo

Global Lupus Therapeutic Market 2017-2021

Global Lupus Therapeutic Market 2017-2021

About Lupus Therapeutic

Lupus is a chronic autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Systemic lupus erythematosus (SLE) is a major disease, which is followed by lupus nephritis at the later stages. Only one drug is approved specifically for the treatment of lupus disorders and the majority of other drugs are off-label based on symptoms. Due to a strong pipeline, the market is expected for more approved drugs for lupus disorders in future.

Technavio’s analysts forecast the global lupus therapeutic market to grow at a CAGR of 9.74% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lupus therapeutic market for 2017-2021. To calculate the market size, the report considers both generic and branded drug market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Lupus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F.Hoffmann-La Roche
  • GlaxoSmithKline
  • Medlmmune
  • Pfizer
Other prominent vendors
  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer HealthCare
  • Biogen
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Immunomedics
  • Kedrion Biopharma
  • LFB Group
  • Merck
  • Novartis
  • Shire
  • Takeda Pharmaceuticals
  • UCB
Market driver
  • High prevalence rate
  • For a full, detailed list, view our report
Market challenge
  • Complexity of disease
  • For a full, detailed list, view our report
Market trend
  • Regenerative therapeutic technologies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Lupus Therapeutic Market 2017-2021

Technavio recognizes the following companies as the key players in the global lupus therapeutic market 2017-2021: F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, and Pfizer.

Other Prominent Vendors in the market are: ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is regenerative therapeutic technologies. The management of lupus using regenerative medicines is increasing, and many vendors are focusing on the development of regenerative medicines. The role of regenerative medicines in autoimmune disease is not explored completely. The recent studies showed that immunomodulation and suppression could be achieved through cellular interaction between therapeutic cells and the individual’s immune system, including anti-inflammatory T-cell responses.”

According to the report, one of the major drivers for this market is high prevalence rate. Lupus is one of the major autoimmune diseases that is associated with multiple symptoms like pain, extreme fatigue, hair loss, cognitive issues, and physical impairments, which disturbs every aspect of individual's lives.

Further, the report states that one of the major factors hindering the growth of this market is complexity of disease. Lupus is associated with multiple symptoms, which increases the complexity in individuals for diagnosis, treatment, and overall management. As per the Centers for Disease Control and Prevention (CDC), many individuals with lupus experiences severe inflammation and continuous damage, which leads to general fatigue, chronic pain, mood disturbances, poor sleep quality, and cognitive impairment. Fatigue is experienced by about 85%-92% of people living with lupus. The individuals with lupus can have a significantly lower quality of life than people with other chronic diseases due to its complexity.



Companies Mentioned

F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
  • An overview of lupus disease
    • Table Signs and symptoms in SLE
  • Market landscape
    • Market overview
      • Table Global lupus therapeutic market snapshot
      • Table Global lupus therapeutics market 2016-2021 ($ millions)
      • Table Opportunity analysis in global lupus therapeutic market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline analysis
    • Table Key clinical trials
  • Market segmentation by drug class
    • Table Segmentation of global lupus therapeutic market by drug class 2016
    • Anti-inflammatory drugs
      • Table Global lupus anti-inflammatory therapeutics market 2016-2021 ($ millions)
    • Corticosteroids
      • Table Global lupus corticosteroid drug market 2016-2021 ($ millions)
    • Immunosuppressant drugs
      • Table Global lupus immunosuppressant drugs market 2016-2021 ($ millions)
    • Antimalarial drugs
      • Table Global Iupus antimalarial drug market 2016-2021 ($ millions)
    • BLyS-specific inhibitors
      • Table Global lupus market for BLyS-specific inhibitors drug segment 2016-2021 ($ millions)
    • Biologicals
      • Table Global lupus biologicals market 2016-2021 ($ millions)
    • Others
      • Table Global Iupus other therapeutics market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global lupus therapeutics market by geography 2016 and 2021
    • Table Global lupus therapeutics market revenue by geography 2016-2021 ($ millions)
    • Lupus therapeutics market in Americas
      • Table Market scenario in Americas
      • Table Lupus therapeutics market in Americas 2016-2021 ($ millions)
    • Lupus therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table Lupus therapeutics market in EMEA 2016-2021 ($ millions)
    • Lupus therapeutics market in APAC
      • Table Market scenario in APAC
      • Table Lupus therapeutic market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Diagnostic tools for lupus disorders
      • Table Various drug classes used as off-label treatment for lupus disorders
    • Market challenges
      • Table Various complex symptoms associated with lupus disorder
      • Table Various side effects associated with lupus treatment
  • Market trends
    • Regenerative therapeutic technologies
      • Table Pipeline of regenerative medicines for lupus disorders
    • Inorganic growth strategies
    • Government initiatives
      • Table Aims of action plans by CDC
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global lupus therapeutics market 2016
      • Table Competitive factors of global lupus therapeutics market
      • Table Market penetration of various vendors worldwide 2016
      • Table Strategic success factors of companies in global lupus therapeutics market
  • Key vendor analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • MedImmune
      • Table MedImmune: Key highlights
      • Table MedImmune: Strength assessment
      • Table MedImmune: Strategy assessment
      • Table MedImmune: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report